Patents Assigned to Kowa Co., Ltd.
  • Publication number: 20220047585
    Abstract: A preventing or treating agent for glaucoma is provided. This drug has a strong action of reducing intraocular pressure such that the intraocular pressure can be reduced even from the normal intraocular pressure. More specifically, a prophylactic or therapeutic agent for glaucoma, a preventing or treating agent for ocular hypertension, and eye drops containing (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl homopiperazine or its salt and phosphoric acid or its salt are provided.
    Type: Application
    Filed: November 1, 2021
    Publication date: February 17, 2022
    Applicant: KOWA CO., LTD.
    Inventors: Shin SUGIMOTO, Ken MIZUNO, Masatoshi TAKAHASHI, Makoto KANEBAKO
  • Publication number: 20210205274
    Abstract: An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): wherein each of R1 and R2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R3a and R3b or R4a and R4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R5 (R5 represents, for example, a hydrogen atom or a C1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O)l group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.
    Type: Application
    Filed: February 26, 2021
    Publication date: July 8, 2021
    Applicant: Kowa Co., Ltd.
    Inventors: Toshiaki TAKIZAWA, Kentaro MURAKAMI
  • Publication number: 20210052599
    Abstract: There is provided a drug therapy for prevention of glaucoma or prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. Disclosed is a combination of (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof, and a prostaglandin for prevention or treatment of glaucoma.
    Type: Application
    Filed: November 10, 2020
    Publication date: February 25, 2021
    Applicant: KOWA CO., LTD.
    Inventor: Ken MIZUNO
  • Publication number: 20200246315
    Abstract: An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): wherein each of R1 and R2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R3a and R3b or R4a and R4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R5 (R5 represents, for example, a hydrogen atom or a C1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O)l group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate the compound or the salt.
    Type: Application
    Filed: April 22, 2020
    Publication date: August 6, 2020
    Applicant: Kowa Co., Ltd.
    Inventors: Toshiaki TAKIZAWA, Kentaro Murakami
  • Patent number: 10568860
    Abstract: The present invention provides a novel nanotechnology-based strategy for therapeutic neovascularization. Said statin-loaded nanoparticle allows local delivery of statin and thus improves therapeutic efficacy of several kind of diseases which may treated by statin such as ischemic neovascularization.
    Type: Grant
    Filed: August 30, 2007
    Date of Patent: February 25, 2020
    Assignees: KOWA CO., LTD., SENTANIRYOUKAIHATSU CO., LTD.
    Inventor: Kensuke Egashira
  • Publication number: 20200030340
    Abstract: There is provided a drug therapy for prevention of glaucoma or prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. Disclosed is a combination of (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof, and a prostaglandin for prevention or treatment of glaucoma.
    Type: Application
    Filed: September 4, 2019
    Publication date: January 30, 2020
    Applicant: KOWA CO., LTD.
    Inventor: Ken MIZUNO
  • Publication number: 20200030299
    Abstract: An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): wherein each of R1 and R2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R3a and R3b or R4a and R4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R5 (R5 represents, for example, a hydrogen atom or a C1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O)l group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.
    Type: Application
    Filed: October 2, 2019
    Publication date: January 30, 2020
    Applicant: Kowa Co., Ltd.
    Inventors: Toshiaki TAKIZAWA, Kentaro MURAKAMI
  • Publication number: 20190328730
    Abstract: A preventing or treating agent for glaucoma is provided. This drug has a strong action of reducing intraocular pressure such that the intraocular pressure can be reduced even from the normal intraocular pressure. More specifically, a prophylactic or therapeutic agent for glaucoma, a preventing or treating agent for ocular hypertension, and eye drops containing (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl homopiperazine or its salt and phosphoric acid or its salt are provided.
    Type: Application
    Filed: July 8, 2019
    Publication date: October 31, 2019
    Applicant: KOWA CO., LTD.
    Inventors: Shin SUGIMOTO, Ken MIZUNO, Masatoshi TAKAHASHI, Makoto KANEBAKO
  • Patent number: 10335306
    Abstract: A supporter includes a body section having a back-contact section, a first auxiliary band section of which one end is fixed to the top end of a left side of the back-contact section and the other end is fixed to the bottom end of a right side of the back-contact section, a second auxiliary band section forming a pair with the first auxiliary band section, a first ring arranged to slide between the one end and the other end of the first auxiliary band section, a second ring forming a pair with the first ring, a first adjustment band section of which one end is fixed to loops on a right end side of the body section and the other end can be fastened to loops on the right end side of the body section, and a second adjustment band section forming a pair with the first adjustment band section.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: July 2, 2019
    Assignees: KOWA CO., LTD, ADVANCING INC., DMCHAIN COOPERATIVE
    Inventors: Hidetaka Okada, Hitoshi Ojima, Hidenori Kaseno
  • Publication number: 20190167644
    Abstract: An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): wherein each of R1 and R2 which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R3a and R3b or R4a and R4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R5 (R5 represents, for example, a hydrogen atom or a C1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O)1 group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.
    Type: Application
    Filed: February 7, 2019
    Publication date: June 6, 2019
    Applicant: Kowa Co. Ltd.
    Inventors: Toshiaki TAKIZAWA, Kentaro MURAKAMI
  • Publication number: 20180185384
    Abstract: There is provided a drug therapy for prevention of glaucoma or prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. Disclosed is a combination of (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof, and a prostaglandin for prevention or treatment of glaucoma.
    Type: Application
    Filed: February 27, 2018
    Publication date: July 5, 2018
    Applicant: KOWA CO., LTD.
    Inventor: Ken MIZUNO
  • Publication number: 20180078530
    Abstract: An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): wherein each of R1 and R2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R3a and R3b or R4a and R4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R5 (R5 represents, for example, a hydrogen atom or a C1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O)l group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.
    Type: Application
    Filed: October 18, 2017
    Publication date: March 22, 2018
    Applicant: Kowa Co., Ltd.
    Inventors: Toshiaki TAKIZAWA, Kentaro MURAKAMI
  • Publication number: 20170020889
    Abstract: There is provided a drug therapy for prevention of glaucoma or prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. Disclosed is a combination of (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof, and a prostaglandin for prevention or treatment of glaucoma.
    Type: Application
    Filed: October 4, 2016
    Publication date: January 26, 2017
    Applicant: KOWA CO., LTD.
    Inventor: Ken MIZUNO
  • Patent number: 9540344
    Abstract: The present invention provides a method capable of industrially producing a target product, i.e., a compound represented by the aforementioned formula (I) or a salt thereof, which is useful for preventing and treating cerebrovascular disorders such as cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, and cerebral edema, particularly for preventing and treating glaucoma, at high yield even on a large scale without imposing a negative impact on the environment. The present invention provides a method for producing a compound represented by formula (I) or a salt thereof, wherein the method comprises a step of reacting a compound represented by formula (III) or a salt thereof with a compound represented by formula (II) in the presence of at least one solvent selected from the group consisting of a nitrile solvent, an amide solvent, a sulfoxide solvent, and a urea solvent, and a base.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: January 10, 2017
    Assignee: KOWA CO., LTD.
    Inventors: Noriaki Gomi, Tadaaki Ohgiya, Kimiyuki Shibuya
  • Patent number: 9526651
    Abstract: A lower leg supporter supports a gastrocnemius muscle from upper, lower, left, and right sides without interfering with movement of an Achilles tendon and which can suppress excessive vibration or deformation of such muscle to reduce a wearer's fatigue. The lower leg supporter includes a first anchor section that secures a tubular knitted fabric to a below-knee part, a second anchor section that secures the tubular knitted fabric to an above-ankle part, and an X-shaped gastrocnemius muscle support section located at a joining part of such muscle and an Achilles tendon on the back surface side of the tubular knitted fabric. Two ends of the X-shaped knitted fabric are joined to the first anchor section to support the gastrocnemius muscle. The other two ends of the X-shaped knitted fabric are joined to the second anchor section, and extend to both edges of the Achilles tendon.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: December 27, 2016
    Assignee: KOWA CO., LTD.
    Inventors: Yoshihiko Kozasa, Hidefumi Koga
  • Publication number: 20160243086
    Abstract: An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): wherein each of R1 and R2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R3a and R3b or R4a and R4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R5 (R5 represents, for example, a hydrogen atom or a C1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O)l group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.
    Type: Application
    Filed: May 3, 2016
    Publication date: August 25, 2016
    Applicant: Kowa Co., Ltd.
    Inventors: Toshiaki TAKIZAWA, Kentaro Murakami
  • Publication number: 20150320748
    Abstract: The present invention is intended to provide a pharmaceutical product for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the present invention is also intended to provide a preventive and/or therapeutic agent for various diseases based on inhibition of expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and the present invention relates to an agent for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and relates also to a preventive and/or therapeutic agent for various diseases based on the inhibition of the expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the agent comprising a compound represented by Formula (I), its salt, or a solva
    Type: Application
    Filed: July 9, 2015
    Publication date: November 12, 2015
    Applicant: KOWA CO., LTD.
    Inventors: Kimiyuki SHIBUYA, Tadaaki Ohgiya, Takeshi Murakami
  • Publication number: 20150306098
    Abstract: The present invention is intended to provide a pharmaceutical product for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the present invention is also intended to provide a preventive and/or therapeutic agent for various diseases based on inhibition of expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and the present invention relates to an agent for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and relates also to a preventive and/or therapeutic agent for various diseases based on the inhibition of the expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the agent comprising a compound represented by Formula (I), its salt, or a solva
    Type: Application
    Filed: July 9, 2015
    Publication date: October 29, 2015
    Applicant: Kowa Co., Ltd.
    Inventors: Kimiyuki SHIBUYA, Tadaaki Ohgiya, Takeshi Murakami
  • Patent number: 9045460
    Abstract: The present invention provides a method capable of industrially producing a target product, i.e., a compound represented by the aforementioned formula (I) or a salt thereof, which is useful for preventing and treating cerebrovascular disorders such as cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, and cerebral edema, particularly for preventing and treating glaucoma, at high yield even on a large scale without imposing a negative impact on the environment. The present invention provides a method for producing a compound represented by formula (I) or a salt thereof, wherein the method comprises a step of reacting a compound represented by formula (III) or a salt thereof with a compound represented by formula (II) in the presence of at least one solvent selected from the group consisting of a nitrile solvent, an amide solvent, a sulfoxide solvent, and a urea solvent, and a base.
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: June 2, 2015
    Assignee: KOWA CO., LTD.
    Inventors: Noriaki Gomi, Tadaaki Ohgiya, Kimiyuki Shibuya
  • Patent number: 9039167
    Abstract: The present invention has a technical object to provide glasses which prevent invasion of pollen, can be continuously worn without any discomfort in wearing, and can effectively block ultraviolet ray. The present invention achieves the technical object by glasses including inwardly projecting visors in rims and end pieces of a frame, and glasses in which lenses, a frame, and inwardly projecting visors formed in the frame are formed of synthetic resin containing an ultraviolet absorbing agent or an ultraviolet scattering agent.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: May 26, 2015
    Assignee: KOWA CO., LTD.
    Inventors: Yoshihiro Miwa, Tadashi Kita